CannabisNewsBreaks

MondayJul 17, 2023 1:14 pm

CannabisNewsBreaks – Institute of Biomedical Research Corp. (MRES) Unveils Meticulously Crafted Line of Teas Sourced from Kenya

Institute of Biomedical Research (OTC: MRES) (doing business as M2Bio Sciences) is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence and evidence-based sustainable products and solutions. M2Bio Sciences today announced the forthcoming launch of a captivating line of teas sourced from the scenic gardens of Kenya. The meticulously crafted collection provides not only an exquisite sensory experience but also delivers exceptional medicinal health benefits. “We are delighted to introduce our exceptional line of purple, white and green teas from Kenya,” said Jeff Robinson, CEO of M2Bio Sciences. “Our…

Continue Reading

FridayJul 14, 2023 3:07 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Study Reveals ‘Most Convincing Evidence’ of CBD’s Anti-Inflammatory Actions in Humans

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced additional findings from its human clinical study HYPER-H21-4, completed last year. “The hypertension study sought to evaluate DehydraTECH-processed cannabidiol (“CBD”) as a potential antihypertensive medication and already achieved primary efficacy and safety objectives. According to the company, the study also demonstrated significant reductions in several pro-inflammatory biomarkers – interleukin (‘IL’) 8, 10 and 18 – known to be linked to cardiovascular disease (‘CVD’) and many other conditions such as asthma, lung diseases, chronic kidney disease, fatty liver disease, type 1 and 2 diabetes, obesity, and rheumatoid arthritis. More specifically, after five weeks of…

Continue Reading

FridayJul 14, 2023 1:21 pm

CannabisNewsBreaks – Cannabis Drinks Expo Gear Up for 2023 Events with ‘Growing the Category’ Theme and Focus

Cannabis Drinks Expo (“CDE”) is preparing for its 2023 events, which include shows at San Francisco and Chicago; the San Francisco expo is slated for July 27, 2023, and the Chicago event is scheduled for Aug. 1, 2023. Last year’s events brought together key players in the industry, including MSO’s, dispensaries, cannabis growers, packaging companies, copackers, flavor suppliers, cannabis drinks brands and service providers, and this year’s events are anticipated to accomplish the same thing — and then some. Expected to be two of the largest global gatherings of cannabis drinks professionals around the world, this year’s events will continue…

Continue Reading

ThursdayJul 13, 2023 3:24 pm

CannabisNewsBreaks — Lift Events and Experiences Announces Inaugural US Cannabis Food & Beverage Event

Lift Events and Experiences will be hosting its first U.S. event: Lift San Francisco. The two-day event will be held on Aug. 3–4, 2023, at the Moscone Convention Center in San Francisco. According to the announcement, the event will feature the inaugural Taste at Lift: Cannabis Food & Beverage Experience, which is designed to allow attendees to participate in exclusive demos, in-depth presentations and expert panels led by the top innovators in the cannabis food, beverage and hospitality space. The first day of the Lift San Francisco event will feature the Lift Cannabis Business Conference & Arcview Investment Summit, with Taste…

Continue Reading

WednesdayJul 12, 2023 11:34 am

CannabisNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Financial Results for Fiscal 2023

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”). “Fiscal 2023 was characterized by remarkable growth and progress as we continue to advance our drug formulations through FDA trials,” said Ram Mukunda, CEO of IGC. “IGC-AD1 is delivering strong results as it progresses through phase 2B trials. We are delighted with the positive headway we are making in clinical trials, and we remain confident in the potential of IGC-AD1 to be a groundbreaking therapy, with the potential to treat Alzheimer’s and to manage devastating symptoms…

Continue Reading

FridayJul 07, 2023 10:49 am

CannabisNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Secures $12M Line of Credit to Strengthen Efforts in Alzheimer’s Research

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has secured a $12 million revolving line of credit from the Hong Kong Branch of O-Bank Co. Ltd. The funding will support IGC’s working capital needs primarily related to its Alzheimer’s research. Bradbury Asset Management (Hong Kong) Limited, a Hong Kong headquartered financial institution managing approximately $2 billion in assets, has collateralized cash assets in support of the line of credit. This follows the recent investment of $3 million in IGC led by four investment funds managed by Bradbury through a private placement, highlighting continued support for the company. “We are…

Continue Reading

ThursdayJul 06, 2023 3:54 pm

CannabisNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces $3M Common Stock Private Placement

IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer's disease, period cramps (dysmenorrhea), premenstrual syndrome ("PMS") and chronic pain, has received strategic investment support. According to an announcement from the company, it has received investments from four funds managed by Bradbury Asset Management (Hong Kong) Limited, a leading asset management firm with more than $2 billion in managed assets. The announcement also noted that additional contributions were received from three unrelated investors. In total, the company has received an estimated $3 million in gross proceeds. “The…

Continue Reading

ThursdayJul 06, 2023 12:48 pm

CannabisNewsBreaks – Alt Pro Expo to Take the Stage in Dallas

Following successful events in North and South America, the Alternative Products Expo (“Alt Pro Expo”), a production of ZJ Events, is coming to the vibrant city of Dallas, Texas. The Dallas Expo 2023 is set to take place at the Kay Bailey Hutchison Convention Center in the heart of downtown from July 13-15, 2023. The center of retail distribution in the American southwest, Dallas is well on its way to becoming one of the largest hubs in the alternative products industry. The burgeoning space is now generating $25 billion in annual revenues in the vaping, hemp and smoke shop segments…

Continue Reading

MondayJul 03, 2023 12:13 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen Hormone than Control

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently completed its animal study HOR-A22-1, which showed that the company’s patented DehydraTECH(TM) technology platform significantly enhanced the oral delivery of the estrogen hormone estradiol. “The study found that the DehydraTECH-estradiol composition resulted in a maximum concentration in the bloodstream (‘Cmax’) of 5.65 ng/mL, which was approximately 900% higher than the control formulation’s Cmax (0.63 ng/mL). Additionally, the use of the DehydraTECH-formulation resulted in a 2,000% increase in the levels of the estrone metabolite, also measured using the Cmax parameter: DehydraTECH-estradiol resulted in a Cmax of 6.49 ng/mL…

Continue Reading

ThursdayJun 22, 2023 11:49 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) 755-201-EB Trial Demonstrates Clinically Important Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced safety and efficacy results from its phase 2 clinical trial. The purpose of the trial, called “755-201-EB,” was to evaluate the safety of INM-755 CBN cream, which consists of the control cream plus the active pharmaceutical ingredient CBN, and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with epidermolysis bullosa (“EB”). According to the announcement, of the 18 participants assessed, chronic itch improved by a clinically meaningful amount in…

Continue Reading